Currently, AG-946 is being evaluated as a potent, oral, small-molecule allosteric activator of wild-type and mutant PKR in clinical trials for low-risk MDS and SCD [60]. The gene discussed is EIF2AK2; the disease is myelodysplastic syndrome.